annb0t
Top 20
MELBOURNE, Australia, Oct. 18, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 September 2023 (Q3 2023). All figures are in AUD$ unless otherwise stated[1] and provided on an unaudited basis. (PRNewsfoto/Telix Pharmaceuticals Limited)
Summary
Total revenue of $133.6M, up from $120.7M (Q2 2023) Fourth consecutive quarter of positive...
>>> Read more: Telix reports fourth consecutive quarter of positive operating cash flow
Summary
Total revenue of $133.6M, up from $120.7M (Q2 2023) Fourth consecutive quarter of positive...
>>> Read more: Telix reports fourth consecutive quarter of positive operating cash flow
